Pentobarbital

Phase 3Small molecule

UUniversity of California, Los Angeles

Pentobarbital is one of 10 small molecule programs targeting Intracranial Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracranial HypertensionActive, not recruiting

Intracranial HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Intracranial Hypertension

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Approved

1 2

Osmitrol

BB. Braun Medical Inc.

Approved

2 3

Ozempic

Novo Nordisk

Phase 3

2 4

Pentothal

AAbbott

Phase 3

1 5

Cisatracurium Besilate

UUniversity Hospital, Clermont-Ferrand

Approved

1 6

Diamox

Teva

Phase 1

4 7

Pentobarbital

UUniversity of California, Los Angeles

Phase 3

1 8

AZD4017

AstraZeneca

Phase 2

1 9

Nacl

Bayer

Preclinical

1 10

Best Medical Care

UUniversity Hospital, Grenoble

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sedation1 trial

A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)

Completed·—·Phase 1·NCT02250820·280 enrolled

Effectiveness1 trial

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1

Withdrawn·UUniversity of California, Los Angeles·Phase 1/2·NCT00123578

Intracranial Hypertension1 trial

Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension

Terminated·HHospital Universitari Son Dureta·Phase 3·NCT00622570·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pentobarbital. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentobarbital compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentobarbital. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of California, Los Angeles

Pentobarbital

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sedation1 trial

Effectiveness1 trial

Intracranial Hypertension1 trial

References

Drug Info

Quick Facts

Related News